Wire · operational-macro
Revamped plan aims to hasten US approval of treatment for ALS
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
Neurosense is accelerating approval for its ALS drug PrimeC by redesigning its Phase 3 study to be shorter and smaller, launching a novel head-to-head trial against Radicava, and leveraging AI for data analysis, aiming to expedite US approval and reduce costs.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Neurosense is rewriting the ALS drug approval playbook with a faster and leaner trial strategy plus direct competitor testing. You need to rethink trial design and comparator strategy this week to seize the new path to market.
◆ Coverage
1 source · 2 Sep 2026
◆ Related on Wire
◆ Topics
Biotechals-treatmentclinical-trialsregulatory-approvaldrug-developmentai-analytics